Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

Roche Digital Pathology Dx System - Roche Digital Pathology Dx system has received an additional 510(k) clearance from the FDA, now including the VENTANA DP 600 slide scanner alongside the previously cleared VENTANA DP 200 slide scanner, digital pathology workflow software, and a display [1] - The VENTANA DP 600 slide scanner has 40 times the capacity of the VENTANA DP 200 and uses the same scanning technology, providing consistent, high-quality images for pathologists [2] - The system aids pathologists in reviewing and interpreting digital images of scanned pathology slides prepared from formalin-fixed paraffin-embedded (FFPE) tissue for clinical diagnosis [3] - The VENTANA DP 600 produces excellent image quality of stained histology slides from patient tissue samples, enhancing diagnostic accuracy, consistency, and speed through high-resolution images and advanced analysis tools [8] Roche's Leadership in Digital Pathology - Roche is the leading provider of pathology lab solutions, offering an end-to-end digital pathology solution from tissue staining to producing high-quality digital images for reliable AI-based image analysis [4] - The company is moving traditionally research-oriented tools into routine clinical practice, driven by the acceleration of immunotherapy and the development of more complex assays [4] - Roche is committed to investing in and shaping the future of pathology, focusing on improving healthcare efficiency and patient care through digital transformation [2][4] Roche's Corporate Background - Founded in 1896 in Basel, Switzerland, Roche is the world's largest biotechnology company and a global leader in in-vitro diagnostics [5] - The company combines strengths in Diagnostics and Pharma with data insights from clinical practice to deliver personalised healthcare [5] - Roche is committed to sustainability, aiming to achieve net zero by 2045 through initiatives like the Science Based Targets and the Sustainable Markets Initiative [6] - Genentech in the United States is a wholly owned member of the Roche Group, and Roche is the majority shareholder in Chugai Pharmaceutical, Japan [6]